Evidence map›Paper›PMID 39804951›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Rescuing ACE2-Deficiency-Mediated Nucleus Pulposus Senescence and Intervertebral Disc Degeneration by a Nanotopology-Enhanced RNAi System.

Kaiqiang Sun, Zijian Kang, Chen Yan, Yan Yu, Linhui Han, Yangyang Shi, Liang Chen, Jiangang Shi, Yu Chen, Jingchuan Sun

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kaiqiang SunDepartment of Orthopedic Surgery, Changzheng Hospital, Naval Medical University, Shanghai, 200003, P. R. China.ORCID https://orcid.org/0000-0002-0272-8383
Zijian KangDepartment of Rheumatology and Immunology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, P. R. China.
Chen YanDepartment of Orthopedic Surgery, Changzheng Hospital, Naval Medical University, Shanghai, 200003, P. R. China.
Yan YuState Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, 200433, P.R. China.
Linhui HanDepartment of Orthopedic Surgery, Changzheng Hospital, Naval Medical University, Shanghai, 200003, P. R. China.
Yangyang ShiDepartment of Orthopedic Surgery, Changzheng Hospital, Naval Medical University, Shanghai, 200003, P. R. China.
Liang ChenState Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, 200433, P.R. China.ORCID https://orcid.org/0000-0002-1437-4308
Jiangang ShiDepartment of Orthopedic Surgery, Changzheng Hospital, Naval Medical University, Shanghai, 200003, P. R. China.ORCID https://orcid.org/0000-0003-2133-0108
Yu ChenMaterdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China.ORCID https://orcid.org/0000-0002-8206-3325
Jingchuan SunDepartment of Orthopedic Surgery, Changzheng Hospital, Naval Medical University, Shanghai, 200003, P. R. China.ORCID https://orcid.org/0000-0002-8956-9409

Funding

Basic Research Program of Shanghai Municipal Government 21JC1406002Chenguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education CommissionHigh Achievement Cultivation Plan of Changzheng Hospital 2020YCGPZ106National Natural Science Foundation of China 82172381;82302760;52102350;82472493Qingnian YingcaiQihang Plan of Shanghai UniversityShanghai Sailing Program 23YF1459100Shanghai Science and Technology Program 21010500100Shanghai Shenkang Project SHDC2020CR1024BShanghai Shuguang Program 21SG39
6 · The paper itself

Abstract

Nucleus pulposus cell (NPC) senescence contributes to intervertebral disc degeneration (IVDD). However, the underlying molecular mechanisms are not fully understood. In this study, it is demonstrated that angiotensin-converting enzyme 2 (ACE2) counteracted the aging of NPCs and IVDD at the cellular and physiological levels. The expression of ACE2 correlates negatively with the degree of NPC senescence and IVDD. Using both loss- and gain-of-function mouse models, it is revealed that ACE2 deficiency increased the senescence of NPCs and exacerbated injury- or instability-induced IVDD, whereas ACE2 overexpression counteracted these detrimental effects. Mechanistically, integrated analysis of single-cell and bulk transcriptomics shows that ACE2 deficiency results in the activation of TGFβ2/Smads signaling pathway and the transcription of Serpine1, ultimately triggering NPC senescence and IVDD. A nanomedical delivery system (virus-like nanovectors, VNs) composed of nanovectors with a virus-like surface topology and small interfering RNA targeting Serpine1 (VN-siSer) is developed. With nanotopology-enhanced transfection efficiency, RNA-interfering treatment by VN-siSer effectively alleviated NPC senescence and IVDD at both the cellular and animal levels. Overall, the data reveal the underlying mechanisms of ACE2 in NPC senescence and IVDD pathogenesis and propose a distinct paradigm of precise nanomedical senescence-blockade RNAi for IVDD treatment.

Indexed as

Angiotensin-Converting Enzyme 2Cellular SenescenceIntervertebral Disc DegenerationNucleus PulposusPeptidyl-Dipeptidase AAnimalsDisease Models, AnimalHumansMiceRNA InterferenceSignal TransductionACE2 protein, humanAce2 protein, mouseAngiotensin-Converting Enzyme 2Peptidyl-Dipeptidase AACE2Cellular senescneceGene therapyIntervertebral disc degenerationNanotopology‐enhanced RNAi system

Identifiers

PMID39804951
PMCPMC11884558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.